Table 1 Baseline and treatment characteristics
|  | All patients (n = 198) |
|---|---|
Age, median (IQR) | 61 (54–66) |
Sex | Â |
 Male | 163 (82.3%) |
 Female | 35 (17.7%) |
Total pack-years | Â |
 < 10 pack-years | 84 (42.0%) |
 ≥ 10 pack-years | 114 (57.6%) |
Alcohol consumption | Â |
 < 20 drinks per week | 149 (75.3%) |
 ≥ 20 drinks per week | 49 (24.7%) |
Primary site | Â |
 Tonsil | 108 (54.5%) |
 Base of tongue | 76 (38.4%) |
 Soft palate | 9 (4.5%) |
 Vallecula | 3 (1.5%) |
 Indeterminate | 2 (1.0%) |
Clinical T-stage | Â |
 T1 | 58 (29.3%) |
 T2 | 140 (70.7%) |
Clinical N-stage | Â |
 N0 | 21 (10.6%) |
 N1 | 52 (26.3%) |
 N2 | 125 (63.1%) |
p16 status | Â |
 Positive | 144 (72.7%) |
 Negative | 28 (14.1%) |
 Unknown | 26 (13.1%) |
Treatment | Â |
 RT | 39 (19.7%) |
 CRT | 159 (80.3%) |
Radiation laterality | Â |
 Unilateral | 14 (7.1%) |
 Bilateral | 163 (82.3%) |
 Unknown | 21 (10.6%) |
CT simulation | Â |
 With contrast | 85 (42.9%) |
 Without contrast | 92 (46.5%) |
 Unknown | 21 (10.6%) |
Chemotherapy regimen | Â |
 Cisplatin | 135 (68.2%) |
  High dose | 83 (61.4%) |
  Weekly | 52 (38.5%) |
 Carboplatinum + 5-fluorouracil | 14 (7.1%) |
 Cetuximab | 5 (2.5%) |
 Other | 5 (2.5%) |